# US 2012/0251593 A1 · Silk fibroin-decorin scaffolds

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2012/0251593 A1
- Document ID: US20120251593A1
- Status: Published application
- Kind: A1
- Application number: 13/498,640
- Filed: 2010-09-28
- Published: 2012-10-04
- Earliest claimed: 2009-09-28
- Assignees: The Baoard of Regents of the University of Texas System
- Inventors: Anshu B. Mathur; Charles E. Butler; Vishal Gupta; Nadja K. Burns
- Web page: https://patentgrep.com/patent/US20120251593A1

## CPC

- C07K 14/43586: {from silkworms}
- A61L 27/26: Mixtures of macromolecular compounds
- A61L 27/3604: {characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel}
- A61L 31/005: {Ingredients of undetermined constitution or reaction products thereof}
- A61L 31/041: {Mixtures of macromolecular compounds}
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- C07K 14/4725: {Proteoglycans, e.g. aggreccan}
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Disclosed are silk fibroin scaffolds that are fabricated with decorin proteoglycan, and methods of using these scaffolds in the repair of tissue defects in subjects. The scaffolds have biomechanical properties which makes them suitable for patient-specific design for defects where strong tensile strength is required, such as musculofascia reconstruction.

## Claims

### Claim 1

A biocompatible scaffold, comprising a silk fibroin polypeptide and a decorin proteoglycan in contact with the silk fibroin polypeptide.

### Claim 2 (depends on 1)

The scaffold of claim 1, wherein the ratio of decorin proteoglycan:silk fibroin polypeptide in the scaffold ranges from about 1:100 (w/w) to about 1:1×108 (w/w).

### Claim 3 (depends on 2)

The scaffold of claim 2, wherein the ratio of decorin proteoglycan:silk fibroin polypeptide in the scaffold ranges from about 1:100 (w/w) to about 1:1×106 (w/w).

### Claim 4 (depends on 3)

The scaffold of claim 3, wherein the ratio of decorin proteoglycan:silk fibroin polypeptide in the scaffold ranges from about 1:100 (w/w) to about 1:1×104 (w/w).

### Claim 5 (depends on 4)

The scaffold of claim 4, wherein the ratio of decorin proteoglycan:silk fibroin polypeptide in the scaffold ranges from about 1:100 (w/w) to about 1:1000 (w/w).

### Claim 6 (depends on 1)

The scaffold of claim 1, further comprising a therapeutic agent.

### Claim 7 (depends on 6)

The scaffold of claim 6, wherein the therapeutic agent is selected from the group consisting of an antimicrobial agent, an anti-inflammatory agent, an immunosuppressant, or a growth factor.

### Claim 8 (depends on 1)

The scaffold of claim 1, wherein the silk fibroin polypeptide comprises 20 amino acids of SEQ ID NO:1.

### Claim 9 (depends on 8)

The scaffold of claim 8, wherein the silk fibroin polypeptide comprises 50 amino acids of SEQ ID NO:1.

### Claim 10 (depends on 9)

The scaffold of claim 9, wherein the silk fibroin polypeptide comprises 100 amino acids of SEQ ID NO:1.

### Claim 11 (depends on 10)

The scaffold of claim 10, wherein the silk fibroin polypeptide comprises SEQ ID NO:1.

### Claim 12 (depends on 1)

The scaffold of claim 1, wherein the scaffold has a thickness of between about 0.1 mm and about 5 mm.

### Claim 13

A method of making a biocompatible scaffold, comprising:
(a) preparing a composition comprising a silk fibroin polypeptide, a decorin proteoglycan, and a solvent to create a blend;
(b) placing the blend onto a surface; and
(c) drying the blend to remove some or all of the solvent, wherein a biocompatible scaffold is formed.

### Claim 14 (depends on 13)

The method of claim 13, further comprising (d) contacting the scaffold of (c) with a composition comprising an alcohol.

### Claim 15 (depends on 14)

The method of claim 14, wherein the alcohol is methanol.

### Claim 16 (depends on 13)

The method of claim 13, further comprising contacting the scaffold of (d) with phosphate buffered saline.

### Claim 17 (depends on 1)

Use of a scaffold of claim 1 in the preparation of a medicament for treating a tissue defect in a subject.

### Claim 18 (depends on 17)

The use of claim 17, wherein the tissue defect is a musculofascia defect of the abdominal wall.

### Claim 19 (depends on 17)

The use of claim 17, wherein the subject is a human.

### Claim 20 (depends on 17)

The use of claim 17, further comprising implanting the scaffold in a subject as part of a surgical procedure directed at repairing a musculofascia defect in a subject.

### Claim 21 (depends on 1)

A kit comprising a scaffold of claim 1 in a sealed container.
